Kantoff PW - Search Results

1

Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study.

Konety BR, Eastham JA, Reuter VE, Scardino PT, Donat SM, Dalbagni G, Russo P, Herr HW, Schwartz L, Kantoff PW, Scher H, Kelly WK. Konety BR, et al. Among authors: kantoff pw. J Urol. 2004 Feb;171(2 Pt 1):709-13. doi: 10.1097/01.ju.0000108122.36893.5a. J Urol. 2004. PMID: 14713792 Clinical Trial.

2

Long-term followup of 150 patients with testicular cancer treated at a single institution.

Kantoff PW, Kalish LA, McDowell-Bryant P, Canellos GP, Gibbs R, Richie JP, Garnick MB. Kantoff PW, et al. J Urol. 1992 Jan;147(1):82-8. doi: 10.1016/s0022-5347(17)37139-2. J Urol. 1992. PMID: 1370332

3

Chemotherapy for muscle-infiltrating bladder cancer.

Scher HI, Kantoff PW. Scher HI, et al. Among authors: kantoff pw. Hematol Oncol Clin North Am. 1992 Feb;6(1):169-78. Hematol Oncol Clin North Am. 1992. PMID: 1556048 Review.

4

Chemotherapy for metastatic bladder cancer.

Kantoff PW, Scher HI. Kantoff PW, et al. Hematol Oncol Clin North Am. 1992 Feb;6(1):195-203. Hematol Oncol Clin North Am. 1992. PMID: 1556050 Review.

5

Constitutive expression of high levels of prostate-specific antigen in the absence of prostate carcinoma.

Kibel AS, Krithivas K, Shamel LB, Kantoff PW, DeWolf WC. Kibel AS, et al. Among authors: kantoff pw. Urology. 1996 Nov;48(5):741-6. doi: 10.1016/S0090-4295(96)00235-X. Urology. 1996. PMID: 8911518

6

Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.

Brufsky A, Fontaine-Rothe P, Berlane K, Rieker P, Jiroutek M, Kaplan I, Kaufman D, Kantoff P. Brufsky A, et al. Urology. 1997 Jun;49(6):913-20. doi: 10.1016/s0090-4295(97)00091-5. Urology. 1997. PMID: 9187700 Clinical Trial.

7

Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma.

Ghossein RA, Rosai J, Scher HI, Seiden M, Zhang ZF, Sun M, Chang G, Berlane K, Krithivas K, Kantoff PW. Ghossein RA, et al. Among authors: kantoff pw. Urology. 1997 Jul;50(1):100-5. doi: 10.1016/S0090-4295(97)00127-1. Urology. 1997. PMID: 9218026

8

Assessment of prostate cancer volume using endorectal coil magnetic resonance imaging: a new predictor of tumor response to neoadjuvant androgen suppression therapy.

D'Amico AV, Chang E, Garnick M, Kantoff P, Jiroutek M, Tempany CM. D'Amico AV, et al. Urology. 1998 Feb;51(2):287-92. doi: 10.1016/s0090-4295(97)00610-9. Urology. 1998. PMID: 9495713

9

Management of hormone refractory prostate cancer: current standards and future prospects.

Oh WK, Kantoff PW. Oh WK, et al. Among authors: kantoff pw. J Urol. 1998 Oct;160(4):1220-9. J Urol. 1998. PMID: 9751323 Review.

10

Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer.

Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR. Duque JL, et al. Among authors: kantoff pw. Urology. 1999 Sep;54(3):523-7. doi: 10.1016/s0090-4295(99)00167-3. Urology. 1999. PMID: 10475365

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

481 results

Search Page

Filters